endo-11-(3-oxocyclohex-1-en-1-yl)-4-phenyl-4,11-diazatricyclo[5.3.1.02,6]undecane-9-ene-3,5,8-trione | 70484-65-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: endo-11-(3-oxocyclohex-1-en-1-yl)-4-phenyl-4,11-diazatricyclo[5.3.1.02,6]undecane-9-ene-3,5,8-trione
• 英文别名: endo-11-(3-oxocyclohexen-1-en-1-yl)-4-phenyl-4,11-diazatricyclo[5.3.1.02,6]undec-9-ene-3,5,8-trione；endo-11-(3-oxocyclohex-1-en-1-yl)-4-phenyl-4,11-diazatricyclo[5.3.1.02,6]undec-9-ene-3,5,8-trione；11-(3-oxocyclohex-1-en-1-yl)-4-phenyl-4,11-diazatricyclo[5.3.1.02,6]undecane-9-ene-3,5,8-trione；11-(3-oxocyclohex-1-en-1-yl)-4-phenyl-4,11-diazatricyclo[5.3.1.02,6]undec-9-ene-3,5,8-trione；11-(3-Oxocyclohexen-1-yl)-4-phenyl-4,11-diazatricyclo[5.3.1.02,6]undec-9-ene-3,5,8-trione
• CAS: 70484-65-0
• 化学式: C₂₁H₁₈N₂O₄
• 分子量: 362.385
• InChiKey: PQNAWMBAJKVJIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Tricyclic compounds and their use in the treatment of cancer
  申请人：Arnér Elias Set Jenö

  公开号：US10881653B2

  公开（公告）日：2021-01-05

  There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein X, Y, Z, R1 and R2 have meanings provided in the description, which compounds are useful in the treatment of cancers.

  提供了式 (I) 的化合物或其药学上可接受的盐类，其中 X、Y、Z、R1 和 R2 的含义见说明，这些化合物可用于治疗癌症。
• TRICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Arnér Elias Set Jenö

  公开号：US20200113889A1

  公开（公告）日：2020-04-16

  There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein X, Y, Z, R 1 and R 2 have meanings provided in the description, which compounds are useful in the treatment of cancers.
• THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER
  申请人：Cinda Pharma AB

  公开号：US20210038577A1

  公开（公告）日：2021-02-11

  The present invention provides inhibitors of thioredoxin reductase, in particular selenium compromised thioredoxin reductase-derived apoptotic protein (SecTRAP) forming agents, for use in treating an immune cell infiltrated cancer (e.g. a T-cell infiltrated cancer) in a subject, wherein said agents stimulate an anti-cancer immune response. The present invention also provides combinations comprising a SecTRAP forming agent and other therapeutic agents for use in treating cancer.